Furthermore, tirzepatide, characterized as a dual agonist targeting GIP and GLP-1, has exhibited efficacy in weight reduction and recently secured approval from the Food and Drug Administration for managing both T2D and obesity [22,25,26]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.